Skip to main content

Vascular Disease

2
Pipeline Programs
8
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 7 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Baxter
BaxterCosta Rica - Cartago
1 program
1
EsmololPhase 4Small Molecule
ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
1
ambrisentanPhase 3
Carvedilol and PlaceboN/A
Sound Pharmaceuticals
1 program
Action ScoreN/A
Pfizer
PfizerNEW YORK, NY
1 program
Action ScoreN/A1 trial
Active Trials
NCT00236210Completed422Est. Jul 2006
Shockwave Medical
Shockwave MedicalCA - Santa Clara
1 program
Shockwave System TreatmentN/A1 trial
Active Trials
NCT01577888Completed6Est. Aug 2014
Abbott
AbbottABBOTT PARK, IL
1 program
XIENCE PRIME SV EECSSN/A1 trial
Active Trials
NCT01115933Completed65Est. Dec 2013
GSK
GSKLONDON, United Kingdom
1 program
ambrisentanPHASE_31 trial
Active Trials
NCT01808313Completed134Est. Aug 2014
Baxter International
1 program
EsmololPHASE_4Small Molecule1 trial
Active Trials
NCT01404767Terminated20Est. Dec 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Baxter InternationalEsmolol
GSKambrisentan
Shockwave MedicalShockwave System Treatment
AbbottXIENCE PRIME SV EECSS
PfizerAction Score

Clinical Trials (5)

Total enrollment: 647 patients across 5 trials

NCT01404767Baxter InternationalEsmolol

Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol

Start: Apr 2011Est. completion: Dec 201320 patients
Phase 4Terminated
NCT01808313GSKambrisentan

Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)

Start: Dec 2012Est. completion: Aug 2014134 patients
Phase 3Completed
NCT01577888Shockwave MedicalShockwave System Treatment

Safety and Feasibility Study of the Shockwave Lithoplasty System

Start: Aug 2012Est. completion: Aug 20146 patients
N/ACompleted
NCT01115933AbbottXIENCE PRIME SV EECSS

A Clinical Evaluation of the XIENCE PRIME Small Vessel Everolimus Eluting Coronary Stent System in Japanese Population

Start: Apr 2010Est. completion: Dec 201365 patients
N/ACompleted
NCT00236210PfizerAction Score

A Randomized Controlled Trial of a Novel Community-based Primary and Secondary Cardiovascular Prevention Program

Start: Aug 2004Est. completion: Jul 2006422 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.